ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet


















Novel Biology, Novel Utility, & the Illusion of Skill: What to develop? What to reward?
Draft FDA guidance on anti-infectives for children: It’s (mostly) all about PK and safety
Plazomicin (Achaogen) financial post-mortem: #PassPASTEUR
Language matters: CRE vs. CPE; SDD vs. I; and MDR, XDR, PDR, UDR vs. DTR
Reimbursing for innovative antibiotics / Encouraging updates from the AMR conference
FDA AMDAC – Developing Single-Pathogen agents for P. aeruginosa and A. baumannii
New mechanisms for antibiotic reimbursement in the United States: CMS’s IPPS FY2020 Final Rule
Draft EMA antibacterial guidance: Analysis
Assessing antibiotic value: DTR, fire extinguishers, and a view from Australia
Push! Pull! Push! Pull! / Highlights from Davos 2018
Lancet: 10-20-30 targets to address AMR by 2030
FDA: Early endpoints and late endpoints suggest a path to global regulatory convergence (Bart et al.)
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet

The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet